Log In
Print
BCIQ
Print
Print this Print this
 

Lucentis, ranibizumab (RG3645)

Also known as: formerly rhuFab V2

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionHumanized mAb fragment against VEGF-A
Molecular Target Vascular endothelial growth factor A (VEGF-A)
Mechanism of ActionVascular endothelial growth factor A (VEGF-A) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$25.0M

$28.5M

$200.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today